Northwestern Study on Rituximab Serves Up Scary Reminders

A recent study linking rituximab to a fatal brain virus in the journal Blood is a reminder that no matter the excitement caused by new drugs or therapies, we need to practice a certain degree of due diligence before undergoing them ourselves or allowing loved ones to do so.

The study, out of Northwestern University's Feinberg School of Medicine and led by Dr. Charles Bennett and his innovative RADAR Project (Research on Adverse Drug Events and Reports), linked rituximab to progressive multifocal leukoencephalitis (PML), a fatal brain disease that is often misdiagnosed as early-stage Alzheimer's.

Just a few days ago I wrote about the results of a review by the prestigious Cochran Library, which strongly advocated rituximab to patients with follicular lymphoma.

The Cochran review only confirmed for many what they already knew—that for many lymphoma patients, rituximab has been nothing short of a game-changer.

The RADAR project's findings, meanwhile, only added weight to what some have feared to be true since 2006—that for some people, rituximab might be life-threatening.

However, it's too early to say how rituximab and PML might be linked, or which potential patients might be at risk.

Lymphoma patients aren't the only ones who have benefitted from rituximab; people with rheumatoid arthritis as well as (off-label) those with multiple sclerosis, lupus and anemia have too. What's frightening is that rituximab is now the third monoclonal antibody to be linked with PML; the first was efalizumab (Raptiva), the next was natalizumab (Tysabri) . Both drugs were removed from the US market; Tysabri eventually returned, with new warnings.

As Dr. Bennett told Science Daily (my primary source for this blog entry), "People have been lulled into a false sense of security that this drug is harmless and that it only does good things. No drug is perfect."

Hallelujah. And thank goodness for the likes of the RADAR project (more on them later).

Bennett further recommended that all patients taking rituximab should be closely monitored for neurological symptoms that might indicate PML, including 'forgetfulness, disorientation or mood changes'.

Sources:
--Science Daily's report on rituximab and PML
--UPI piece announcing Raptiva's removal from the US market
--Biogen letter announcing changes to Tysabri's safety and confirming its return to the US market.
--MedScape piece about projects like RADAR that try to bring adverse drug events (ADE) to publication sooner than they would otherwise be.

Lymphoma Treatment Center

Insurance Accepted.
Innovative Lymphoma Treatments.
Call 415-343-6162 Today

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...